SRR1334847
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.514
- PANCREAS_BETA_CELLS+0.428
- TNFA_SIGNALING_VIA_NFKB+0.427
- KRAS_SIGNALING_DN+0.361
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.356
- INFLAMMATORY_RESPONSE+0.346
- HYPOXIA+0.341
- MYOGENESIS+0.308
- COAGULATION+0.282
- IL6_JAK_STAT3_SIGNALING+0.275
Top 10 suppressed
- PROTEIN_SECRETION-0.481
- OXIDATIVE_PHOSPHORYLATION-0.442
- G2M_CHECKPOINT-0.436
- MITOTIC_SPINDLE-0.427
- E2F_TARGETS-0.418
- MYC_TARGETS_V1-0.396
- DNA_REPAIR-0.350
- HEME_METABOLISM-0.314
- UV_RESPONSE_DN-0.247
- ADIPOGENESIS-0.234
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1489821 | GTEX | — | 0.931 |
| 2 | SRR1332317 | GTEX | — | 0.928 |
| 3 | SRR1315866 | GTEX | — | 0.870 |
| 4 | SRR1317494 | GTEX | — | 0.870 |
| 5 | SRR1343879 | GTEX | — | 0.863 |
| 6 | SRR1316392 | GTEX | — | 0.863 |
| 7 | SRR1322456 | GTEX | — | 0.863 |
| 8 | SRR1442666 | GTEX | — | 0.861 |
| 9 | SRR1355150 | GTEX | — | 0.859 |
| 10 | 22e9b9d1-ac71-43f5-8606-f9f53c6ecc08 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.514 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.428 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.427 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.361 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.356 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.346 | Idelalisib | — uncovered |
| HYPOXIA | 0.341 | Idelalisib | — uncovered |
| MYOGENESIS | 0.308 | Inavolisib | — uncovered |
| COAGULATION | 0.282 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.275 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.252 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.238 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.198 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.187 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.184 | Idelalisib | — uncovered |
| APOPTOSIS | 0.177 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.176 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.174 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.161 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.152 | Inavolisib | — uncovered |